Session: FP28-Thyroid Autoimmunity
Room 103 (Moscone Center)
Poster Board SUN-435
Methods. Patients with mild to moderate ophtalmopathy, with less than one year of evolution, and naive to treatment were randomized to receive treatment during 12 months with either 1) bromocriptine (5 mg twice a day) + methimazol (30 mg/day), 2) pentoxifylline (400 mg twice a day) + methimazol (30 mg/day), or 3) methimazol only (30 mg/day). They completed 10 visits to evaluate proptosis and clinical activity score (CAS). In addition, in the first and last visit the quality of life questionnaire specific for Graves’ ophtalmopathy (GO-QOL) was applied.
Results. This is a preliminary report with the results of 25 patients that have concluded the study. Nine were assigned to group 1, eight to group 2, and eight to group 3. General characteristics and baseline measures did not differ between groups. At the end of treatment a favorable change in proptosis was documented in the group receiving bromocriptine (right eye 19.5 to 17.2 mm and left eye 19.2 to 17.1 mm, P<0.001 for both) and pentoxifylline (right eye 19.6 to 17.7 and left eye 19.7 to 18 mm, P= 0.006 for both) and not in the group receiving methimazol (right eye 19.4 to 18.6 mm, P= 0.22 and left eye 18 to 18.3, P= 0.47). A favorable change in the CAS was observed in all groups (P= 0.026, P= 0.011, and P= 0.011, respectively). The QOL score improved significantly in all groups (P= 0.011, P= 0.017, and P= 0.012).
Conclusions. Treatment of mild to moderate Graves’ associated ophtalmopathy with bromocriptine and pentoxfylline was associated with a significant, favorable change in proptosis. Improvement of CAS and QOL were observed with all treatments.
Nothing to Disclose: PA, DC, MAG, FC, BP, AA, FJG
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters